16/05/2022

THAILAND DAILY

NEWSPAPER / MAGAZINE / PUBLISHER

trial-of-new-oral-drug-against-covid-19-begins-in-south-africa

Trial of new oral drug against Covid-19 begins in South Africa

South Africa has been struggling with its plans to achieve the herd immunity through vaccinations, with widespread vaccine hesitancy, largely fuelled by social media misinformation

Topics

Coronavirus | Coronavirus Tests | Coronavirus Vaccine

Oravax Medical Inc, a subsidiary of US/Israeli pharmaceutical company Oramed, has started the first phase of clinical trial of its oral COVID-19 vaccine in South Africa.

South Africa has been struggling with its plans to achieve the herd immunity through vaccinations, with widespread vaccine hesitancy, largely fuelled by social media misinformation.

There is also a strong anti-vaccination lobby, including some political parties.

“We expect to rapidly complete this study and hope to advance into pivotal trials for emergency use approval in countries where our oral Virus-Like Particles (VLP) vaccine would have the greatest impact, Oramed Chief Executive Officer Nadav Kidron said in a statement.

South Africa is a great location for the Phase 1 study, as it is currently experiencing a surge in COVID cases and has struggled to obtain sufficient vaccines.

It is our firm belief that an oral vaccine which eliminates syringes and eases distribution and administration, can significantly help increase vaccination rates for South Africa and similar countries,” Kidron said.

The open-label trial involves participants who have not received either a COVID-19 vaccine or contracted the virus. Participants will be administered one dose of the oral vaccine at the beginning of the trial and a second dose three weeks later.

The trial’s endpoints will include safety and tolerability as well as efficacy by measuring the presence of an immunogenic response.

Kidron said the trial phase would be short to show as quickly as possible that this oral vaccine works very well on humans before seeking phase two approvals.

Oravax said its oral vaccine targets three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, thus making the vaccine potentially more effective against current and future variants of the COVID-19 virus.

Oravax’s VLP vaccine technology is highly scalable for manufacturing and is easily transferable for logistical wide scale distribution as there is no need for subfreezing storage, it added.

Oravax Medical Inc. was established earlier this year by Oramed Pharmaceuticals and other shareholders with a mission to bring an oral COVID-19 vaccine to the market.

Specialising in ways to deliver drugs orally, Oramed is currently in an advance stage of trials for the first commercial oral insulin capsule for the treatment of diabetes.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Comments

be the first to comment on this article

Leave a Reply

Your email address will not be published. Required fields are marked *

Take Me Top